Antipsychotic-Induced Sexual Dysfunction and Its Management

다국어 초록 (Multilingual Abstract)

Sexual dysfunction is a common condition in patients taking antipsychotics, and is the most bothersome symptom and adverse drug effect, resulting in a negative effect on treatment compliance. It is known that hyperprolactinemia is a major cause of sexual dysfunction. Based on the blockade of dopamine D2 receptors, haloperidol, risperidone, and amisulpride are classed as prolactin-elevating antipsychotics, while olanzapine, clozapine, quetiapine, ziprasidone, and aripiprazole are classed as prolactin-sparing drugs. Risperidone and the other typical antipsychotics are associated with a high rate of sexual dysfunction as compared to olanzapine, clozapine, quetiapine, and aripiprazole. With regard to treatment in patients suffering from sexual dysfunction, sildenafil was associated with significantly more erections sufficient for penetration as compared to a placebo. Subsequent studies are needed in order to provide physicians with a better understanding of this problem, thereby leading toward efficacious and safe solutions.

참고문헌 (Reference)

1 Knegtering H, "What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?" 28 (28): 109-123, 2003

2 Lee BH, "Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study" 30 : 714-717, 2006

3 Hanssens L, "The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)" 8 : 95-, 2008

4 Crawford AM, "The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations" 26 : 41-54, 1997

5 Finn SE, "Subjective utility ratings of neuroleptics in treating schizophrenia" 20 : 843-848, 1990

6 Gopalakrishnan R, "Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial" 163 : 494-499, 2006

7 Kelly DL, "Sexuality and schizophrenia: a review" 30 : 767-779, 2004

8 Baggaley M, "Sexual dysfunction in schizophrenia: focus on recent evidence" 23 : 201-209, 2008

9 Smith SM, "Sexual dysfunction in patients taking conventional antipsychotic medication" 181 : 49-55, 2002

10 Cutler AJ, "Sexual dysfunction and antipsychotic treatment" 28 (28): 69-82, 2003

11 Kodesh A, "Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study" 26 : 193-195, 2003

12 Small JG, "Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group" 54 : 549-557, 1997

13 Spollen JJ 3rd, "Prolactin levels and erectile function in patients treated with risperidone" 24 : 161-166, 2004

14 Eberhard J, "Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders" 115 : 268-276, 2007

15 Dossenbach M, "Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation" 8 : 195-201, 2005

16 Arvanitis LA, "Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group" 42 : 233-246, 1997

17 Berner MM, "Management of sexual dysfunction due to antipsychotic drug therapy" (1) : 2007

18 Olfson M, "Male sexual dysfunction and quality of life in schizophrenia" 66 : 331-338, 2005

19 Kinon BJ, "Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine" 31 : 577-588, 2006

20 Lambert M, "Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence" 19 : 415-422, 2004

21 Borison RL, "ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. Seroquel Study Group" 16 : 158-169, 1996

22 Dossenbach M, "IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol" 65 : 312-321, 2004

23 Mullen B, "Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone" 48 : 155-158, 2001

24 Bobes J, "Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study" 29 : 125-147, 2003

25 Turrone P, "Elevation of prolactin levels by atypical antipsychotics" 159 : 133-135, 2002

26 Kasper S, "Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia" 6 : 325-337, 2003

27 Dossenbach M, "Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study" 21 : 251-258, 2006

28 Tran PV, "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" 17 : 407-418, 1997

29 Aizenberg D, "Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine" 62 : 541-544, 2001

30 Mir A, "Change in sexual dysfunction with aripiprazole: a switching or add-on study" 22 : 244-253, 2008

31 Potkin SG, "Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder" 60 : 681-690, 2003

32 Marder SR, "Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials" 61 : 123-136, 2003

33 Pigott TA, "Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study" 64 : 1048-1056, 2003

34 Casey DE, "Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study" 166 : 391-399, 2003

35 Knegtering H, "Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin?" 33 : 711-717, 2008

36 Haddad PM, "Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management" 64 : 2291-2314, 2004

37 Bitter I, "Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients" 20 : 19-21, 2005

38 Costa AM, "A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia" 124 : 291-297, 2006

39 Knegtering R, "A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning" 24 : 56-61, 2004

40 Knegtering H, "A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning" 32 : 315-326, 2006

41 Kelly DL, "A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia" 31 : 340-346, 2006

42 Serretti A, "A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics" 26 : 130-140, 2011

43 McQuade RD, "A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study" 65 (65): 47-56, 2004

44 King DJ, "A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia" 137 : 139-146, 1998